LongeVC co-founder Garri Zmudze was interviewed by THE HORIZONS Life ahead of the Longevity Investors Conference in Gstaad. Garri discussed the sector's growth, projected to reach $67B by 2035, and how LongeVC separates real science from investment narratives: peer-reviewed validation, clear clinical endpoints, and mechanisms that hold up to scrutiny.
He also shared the personal story behind co-founding the firm and highlighted the work of portfolio companies Rubedo Life Sciences and Unnatural Products, as well as LongeVC partner Insilico Medicine.
Read the full interview here.
He also shared the personal story behind co-founding the firm and highlighted the work of portfolio companies Rubedo Life Sciences and Unnatural Products, as well as LongeVC partner Insilico Medicine.
Read the full interview here.